Modification of vasomotor symptoms after various treatment modalities in the postmenopause.
Carranza-Lira
S
S
Gynecologic Endocrinology Service, Hospital de Gineco-Obstetricia 'Luis Castelazo Ayala', Instituto Mexicano del Seguro Social, Mexico, D.F., Mexico. scarranzal@mexis.com
Cortés-Fuentes
E
E
D003000:Clonidine / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D019584:Hot Flashes / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D011433:Propranolol / Q000627:therapeutic use; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D004966:Estrogens, Conjugated (USP); D014665:Vasodilator Agents; D013469:Sulpiride; D011433:Propranolol; D003000:Clonidine; C027429:veralipride